MODULECO HEALTHCARE LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
Company Registration No. 06627288 (England and Wales)
MODULECO HEALTHCARE LIMITED
COMPANY INFORMATION
Directors
Mrs A Boote
Mr A Wilson
Secretary
Mrs A Boote
Company number
06627288
Registered office
Solutions House
39 Quayside
Grosvenor Wharf Road
Ellesmere Port
CH65 4AY
Auditor
DSG Audit
Castle Chambers
43 Castle Street
Liverpool
L2 9TL
MODULECO HEALTHCARE LIMITED
CONTENTS
Page
Strategic report
1 - 2
Directors' report
3
Directors' responsibilities statement
4
Independent auditor's report
5 - 7
Statement of income and retained earnings
8
Balance sheet
9
Statement of changes in equity
10
Notes to the financial statements
11 - 21
MODULECO HEALTHCARE LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 1 -

The directors present the strategic report for the year ended 31 December 2025.

Principal activities

The principal activity of the company continued to be that of the provision of modular healthcare buildings.

Review of the business

The performance of the company during the financial year was in line with directors’ expectations. Hire income has remained stable in the year at £11.7 million (2024: £12.2 million). In addition, turnover in the prior year included £1.4 million relating to the sale of a stock theatre with no similar sale in 2025.

 

The company recorded a profit before taxation of £6.6m (2024: £3.9m). The results in the current year included a one-off profit on disposal of tangible assets of £2.7m.

 

The company has adequate financial resources to meet its current requirements and a satisfactory sales pipeline.

 

Given the nature of the company’s business, and the direct involvement of the directors in the management of the company’s operations, the directors are of the opinion that using non-financial key performance indicators is not necessary for an understanding of the development, performance or position of the business.

Principal risks and uncertainties

The process of risk acceptance and risk management is addressed through a framework of policies, procedures and internal controls. All policies are subject to approval by the board and ongoing review by management.

 

Price risk

The company is not exposed to price risk arising from financial instruments. Prices are set at competitive levels compared to those of other companies operating in the market and the company continues to source new opportunities.

 

Credit risk

The customers of the company are primarily NHS Trusts. On this basis, the directors believe that the company has very minimal exposure to any form of credit risk. The company has robust procedures for dealing with any credit related incident to minimise any potential losses arising.

 

Liquidity risk

The directors regularly review trading results and cashflows (both historical and forecast) to ensure that adequate resources are available. Liquidity remains strong with cash and cash equivalents at £3.0m at 31st December 2025 (£3.3m at 31st December 2024).

 

Cashflow and interest rate risk

The company's performance to date has allowed it to finance its operations from working capital and the company has sufficient cash resources to meet its current requirements.

Key performance indicators

The following key performance indicators have been identified by the board as most relevant to measure the performance of the company:

 

Hire revenue        £11.7m (2024: £12.2)

 

Gross profit        £9.3m (2024: £6.9m)

 

Cash at bank        £3.0m (2024: £3.3m)

MODULECO HEALTHCARE LIMITED
STRATEGIC REPORT (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -

On behalf of the board

Mrs A Boote
Director
9 September 2026
MODULECO HEALTHCARE LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -

The directors present their annual report and financial statements for the year ended 31 December 2025.

Results and dividends

The results for the year are set out on page 8.

Ordinary dividends were paid amounting to £4,000,000 (2024: £3,000,000).

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Mrs A Boote
Mr A Wilson
Auditor

The auditor, DSG Audit, is deemed to be reappointed under section 487(2) of the Companies Act 2006.

Strategic report

The company has chosen in accordance with Companies Act 2006, s. 414C(11) to set out in the company's strategic report information required by Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008, Sch. 7 to be contained in the directors' report. It has done so in respect of its principal activities and financial instruments.

Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

On behalf of the board
Mrs A Boote
Director
9 September 2026
MODULECO HEALTHCARE LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025
- 4 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

MODULECO HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MODULECO HEALTHCARE LIMITED
- 5 -
Opinion

We have audited the financial statements of Moduleco Healthcare Limited (the 'company') for the year ended 31 December 2025 which comprise the statement of income and retained earnings, the balance sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

MODULECO HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MODULECO HEALTHCARE LIMITED (CONTINUED)
- 6 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Discussions with and enquiries of management and those charged with governance were held with a view to identifying those laws and regulations that could be expected to have a material impact on the financial statements. During the engagement team briefing, the outcomes of these discussions and enquiries were shared with the team, as well as consideration as to where and how fraud may occur in the entity.

 

The following laws and regulations were identified as being of significance to the entity:

 

Audit procedures undertaken in response to the potential risks relating to irregularities (which include fraud and non-compliance with laws and regulations) comprised of: inquiries of management and those charged with governance as to whether the entity complies with such laws and regulations; enquiries with the same concerning any actual or potential litigation or claims; inspection of relevant legal correspondence; review of board minutes; testing the appropriateness of journal entries and the performance of analytical review to identify unexpected movements in account balances which may be indicative of fraud.

No instances of material non-compliance were identified. However, the likelihood of detecting irregularities, including fraud, is limited by the inherent difficulty in detecting irregularities, the effectiveness of the entity’s controls, and the nature, timing and extent of the audit procedures performed. Irregularities that result from fraud might be inherently more difficult to detect than irregularities that result from error. As explained above, there is an unavoidable risk that material misstatements may not be detected, even though the audit has been planned and performed in accordance with ISAs (UK).

MODULECO HEALTHCARE LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF MODULECO HEALTHCARE LIMITED (CONTINUED)
- 7 -

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Andrew Moss BA FCA (Senior Statutory Auditor)
For and on behalf of DSG Audit, Statutory Auditor
Chartered Accountants
Castle Chambers
43 Castle Street
Liverpool
L2 9TL
9 September 2026
MODULECO HEALTHCARE LIMITED
STATEMENT OF INCOME AND RETAINED EARNINGS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
2025
2024
Notes
£
£
Turnover
3
11,696,967
13,637,325
Cost of sales
(2,444,096)
(6,746,547)
Gross profit
9,252,871
6,890,778
Administrative expenses
(671,041)
(611,039)
Operating profit
4
8,581,830
6,279,739
Interest receivable and similar income
7
105,766
83,009
Interest payable and similar expenses
8
(2,120,325)
(2,487,227)
Profit before taxation
6,567,271
3,875,521
Tax on profit
9
(1,827,852)
(913,241)
Profit for the financial year
4,739,419
2,962,280
Retained earnings brought forward
21,319,497
21,357,217
Dividends
10
(4,000,000)
(3,000,000)
Retained earnings carried forward
22,058,916
21,319,497

The notes on pages 11 to 21 form part of these financial statements.

MODULECO HEALTHCARE LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 9 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
11
32,452,505
38,979,270
Current assets
Stocks
12
55,209
55,209
Debtors
13
19,608,683
19,889,373
Cash at bank and in hand
3,041,037
3,257,589
22,704,929
23,202,171
Creditors: amounts falling due within one year
14
(10,242,845)
(11,572,922)
Net current assets
12,462,084
11,629,249
Total assets less current liabilities
44,914,589
50,608,519
Creditors: amounts falling due after more than one year
15
(20,676,380)
(26,761,457)
Provisions for liabilities
Deferred tax liability
17
1,133,293
1,481,565
(1,133,293)
(1,481,565)
Net assets
23,104,916
22,365,497
Capital and reserves
Called up share capital
19
3
3
Share premium account
1,045,997
1,045,997
Profit and loss reserves
22,058,916
21,319,497
Total equity
23,104,916
22,365,497

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 9 September 2026 and are signed on its behalf by:
Mrs A Boote
Director
Company registration number 06627288 (England and Wales)
MODULECO HEALTHCARE LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
Share capital
Share premium account
Profit and loss reserves
Total
£
£
£
£
Balance at 1 January 2024
3
1,045,997
21,357,217
22,403,217
Year ended 31 December 2024:
Profit and total comprehensive income for the year
-
-
2,962,280
2,962,280
Dividends
10
-
-
(3,000,000)
(3,000,000)
Balance at 31 December 2024
3
1,045,997
21,319,497
22,365,497
Year ended 31 December 2025:
Profit and total comprehensive income for the year
-
-
4,739,419
4,739,419
Dividends
10
-
-
(4,000,000)
(4,000,000)
Balance at 31 December 2025
3
1,045,997
22,058,916
23,104,916
MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 11 -
1
Accounting policies
Company information

Moduleco Healthcare Limited is a private company limited by shares incorporated in England and Wales. The registered office is Solutions House, 39 Quayside, Grosvenor Wharf Road, Ellesmere Port, CH65 4AY.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of Solutions Topco Limited. These consolidated financial statements are available from its registered office, Solutions House, 39 Quayside, Grosvenor Wharf Road, Ellesmere Port, United Kingdom, CH65 4AY.

1.2
Going concern

The directors have considered the company’s cash flow forecasts, funding arrangements, and operational resilience. Based on this assessment, which includes consideration of the company’s ability to meet its obligations as they fall due for a period of at least twelve months from the date of approval of the financial statements, the directors are satisfied that the company has adequate resources to continue in operational existence for the foreseeable future.true

 

Accordingly, the financial statements have been prepared on a going concern basis.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rental income from operating leases is recognised on a straight line basis over the course of the lease.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses. Cost includes enabling works, delivery and installation of the modular buildings as well as professional fees incurred relating to the transaction.

MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 12 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
8% straight line
Fixtures, fittings & equipment
25% reducing balance
Motor vehicles
25% reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 13 -
1.8
Financial instruments

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans and loans from fellow group companies, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 14 -
Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13

New or Revised Standards

Amendments to FRS 102 issued in September 2024 will apply to the company for accounting periods commencing on or after 1 January 2026. These amendments include significant changes to lease accounting and revenue recognition, together with additional disclosure requirements. The directors are currently assessing the impact of these amendments on the company’s future financial statements.

MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 15 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Determining and reassessing residual values and useful economic lives of tangible assets

The company depreciates tangible assets, over their estimated useful lives. In determining appropriate useful lives of assets, the directors have considered historic performance as well as future expectations for factors such as expected usage of the asset, physical wear and tear, technical and commercial obsolescence and legal limitations of the usage of the asset, such as lease terms. The actual lives of these assets can vary depending on a variety of factors, including technological innovation, product life cycles and maintenance programmes.

 

Judgement is applied to determine the residual values for tangible assets. When determining the residual values, the directors have assessed the amount that the group would currently obtain for the disposal of the asset, if it were already of the condition expected at the end of its useful economic life. At each reporting date, the directors have also assessed whether there have been any indicators, such as a change in how the asset is used, significant unexpected wear and tear and changes in market prices, which suggest previous estimates may differ from current expectations. Where this is the case, the residual value and/or useful life is amended and accounted for on a prospective basis.

3
Turnover and other revenue

An analysis of the company's turnover is as follows:

2025
2024
£
£
Turnover analysed by class of business
Sale of goods and services
11,696,967
12,223,032
Other income
-
1,414,293
11,696,967
13,637,325
2025
2024
£
£
Turnover analysed by geographical market
United Kingdom
11,696,967
13,637,325
2025
2024
£
£
Other revenue
Interest income
105,766
83,009
MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 16 -
4
Operating profit
2025
2024
Operating profit for the year is stated after charging/(crediting):
£
£
Auditors' remuneration
8,250
7,300
Depreciation of owned tangible fixed assets
3,967,545
4,494,200
(Profit)/loss on disposal of tangible fixed assets
(2,688,194)
1,197
Operating lease charges
7,508
7,212
5
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Administration
12
11

Their aggregate remuneration comprised:

2025
2024
£
£
Wages and salaries
438,935
389,457
Social security costs
61,261
75,106
Pension costs
17,414
16,832
517,610
481,395
6
Directors' remuneration
2025
2024
£
£
Remuneration for qualifying services
183,010
210,878
Company pension contributions to defined contribution schemes
4,403
4,329
187,413
215,207

The number of directors for whom retirement benefits are accruing under defined contribution schemes amounted to 2 (2024 - 2).

MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
6
Directors' remuneration
(Continued)
- 17 -
Remuneration disclosed above include the following amounts paid to the highest paid director:
2025
2024
£
£
Remuneration for qualifying services
n/a
104,974
Company pension contributions to defined contribution schemes
n/a
2,201

As total directors' remuneration was less than £200,000 in the current year, no disclosure is provided for the year.

7
Interest receivable and similar income
2025
2024
£
£
Interest income
Interest on bank deposits
105,766
83,009
8
Interest payable and similar expenses
2025
2024
£
£
Interest on other borrowings
2,120,325
2,475,535
Other interest
-
0
11,692
2,120,325
2,487,227
9
Taxation
2025
2024
£
£
Current tax
UK corporation tax on profits for the current period
2,178,823
1,045,810
Adjustments in respect of prior periods
(2,699)
(200,375)
Total current tax
2,176,124
845,435
Deferred tax
Origination and reversal of timing differences
(348,272)
67,806
Total tax charge
1,827,852
913,241
MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
9
Taxation
(Continued)
- 18 -

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Profit before taxation
6,567,271
3,875,521
Expected tax charge based on the standard rate of corporation tax in the UK of 25% (2024: 25%)
1,641,818
968,880
Effects of:
Expenses that are not deductible in determining taxable profit
(1,397,627)
(792,961)
Adjustments in respect of prior years
(2,699)
(200,375)
Group relief
(1,125)
(68,058)
Permanent capital allowances in excess of depreciation
1,587,485
1,005,755
Taxation charge in the financial statements
1,827,852
913,241
10
Dividends
2025
2024
£
£
Interim paid
4,000,000
3,000,000
11
Tangible fixed assets
Plant and machinery
Fixtures, fittings & equipment
Motor vehicles
Total
£
£
£
£
Cost
At 1 January 2025
69,354,329
36,826
50,340
69,441,495
Additions
23,939
3,085
25,560
52,584
Disposals
(3,467,430)
-
0
-
0
(3,467,430)
At 31 December 2025
65,910,838
39,911
75,900
66,026,649
Depreciation and impairment
At 1 January 2025
30,418,393
31,247
12,585
30,462,225
Depreciation charged in the year
3,949,551
2,166
15,828
3,967,545
Eliminated in respect of disposals
(855,626)
-
0
-
0
(855,626)
At 31 December 2025
33,512,318
33,413
28,413
33,574,144
Carrying amount
At 31 December 2025
32,398,520
6,498
47,487
32,452,505
At 31 December 2024
38,935,936
5,579
37,755
38,979,270
MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 19 -
12
Stocks
2025
2024
£
£
Finished goods and goods for resale
55,209
55,209
13
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
2,320,780
2,832,976
Corporation tax recoverable
241,849
-
0
Amounts owed by group undertakings
16,957,385
16,980,740
Prepayments and accrued income
88,669
75,657
19,608,683
19,889,373

Amounts owed by group undertakings are interest free, have no fixed date of repayment and are repayable upon demand.

14
Creditors: amounts falling due within one year
2025
2024
Notes
£
£
Other borrowings
16
5,063,561
5,377,158
Trade creditors
258,774
180,932
Corporation tax
-
0
425,127
Other taxation and social security
579,398
890,102
Other creditors
7,649
6,291
Accruals and deferred income
4,333,463
4,693,312
10,242,845
11,572,922
15
Creditors: amounts falling due after more than one year
2025
2024
£
£
Other borrowings
16
20,676,380
26,761,457
Amounts included above which fall due after five years are as follows:
Payable by instalments
6,275,543
8,625,210
MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 20 -
16
Loans and overdrafts
2025
2024
£
£
Other loans
25,739,941
32,138,615
Payable within one year
5,063,561
5,377,158
Payable after one year
20,676,380
26,761,457

Other borrowings are secured by fixed charges over the assets of the company.

Other loans relate to finance received from De Lage Landen Leasing Limited. These borrowings relate to a number of different agreements with interest rates varying depending on the terms set out in the relevant loan document. The maturity dates for the borrowings are between February 2026 and April 2035. Interest is charged on these loans at varying rates between 4% and 10%.

17
Deferred taxation

Deferred tax assets and liabilities are offset where the company has a legally enforceable right to do so. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:

Liabilities
Liabilities
2025
2024
Balances:
£
£
Accelerated capital allowances
1,133,293
1,481,565
2025
Movements in the year:
£
Liability at 1 January 2025
1,481,565
Credit to profit or loss
(348,272)
Liability at 31 December 2025
1,133,293
18
Retirement benefit schemes
2025
2024
Defined contribution schemes
£
£
Charge to profit or loss in respect of defined contribution schemes
17,414
16,832

The company operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the company in an independently administered fund.

MODULECO HEALTHCARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 21 -
19
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
3
3
3
3
20
Operating lease commitments

At the reporting end date the company had the following contracted future income:

2025
2024
Future amounts receivable under operating leases:
£
£
Within 1 year
10,047,000
10,993,000
Years 2-5
26,026,000
32,194,000
After 5 years
8,602,000
12,021,000
44,675,000
55,208,000
21
Related party transactions

The company has taken advantage of the exemption under FRS 102 not to disclose transactions between group entities on the grounds that it is a wholly-owned subsidiary undertaking.

22
Ultimate controlling party

The immediate parent undertaking is MCH Intermediate Limited.

 

The ultimate parent company is Solutions Topco Limited, a company incorporated in Great Britain and registered in England and Wales. The registered office is Solutions House, 39 Quayside, Grosvenor Wharf Road, Ellesmere Port, United Kingdom, CH65 4AY. Solutions Topco Limited prepares consolidated financial statements which includes Moduleco Healthcare Limited.

 

The smallest and largest group into which the results of this entity are consolidated is that headed by Solutions Topco Limited.

 

The directors are of the opinion that there is no ultimate controlling party of Solutions Topco Limited.

2025-12-312025-01-01falsefalsefalseCCH SoftwareCCH Accounts Production 2026.200Mr A WilsonMr A WilsonMrs A Boote066272882025-01-012025-12-3106627288bus:CompanySecretaryDirector12025-01-012025-12-3106627288bus:Director12025-01-012025-12-3106627288bus:CompanySecretary12025-01-012025-12-3106627288bus:Director22025-01-012025-12-3106627288bus:RegisteredOffice2025-01-012025-12-31066272882025-12-31066272882024-01-012024-12-3106627288core:RetainedEarningsAccumulatedLosses2024-01-012024-12-3106627288core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3106627288core:RetainedEarningsAccumulatedLosses2024-12-3106627288core:RetainedEarningsAccumulatedLosses2023-12-3106627288core:ShareCapital2025-12-3106627288core:ShareCapital2024-12-3106627288core:SharePremium2025-12-3106627288core:SharePremium2024-12-3106627288core:RetainedEarningsAccumulatedLosses2025-12-3106627288core:RetainedEarningsAccumulatedLosses2024-12-31066272882024-12-3106627288core:ShareCapital2023-12-3106627288core:SharePremium2023-12-3106627288core:ShareCapitalOrdinaryShareClass12025-12-3106627288core:ShareCapitalOrdinaryShareClass12024-12-3106627288core:WithinOneYear2025-12-3106627288core:WithinOneYear2024-12-3106627288core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3106627288core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3106627288core:Non-currentFinancialInstrumentscore:AfterOneYear2025-12-3106627288core:Non-currentFinancialInstrumentscore:AfterOneYear2024-12-3106627288core:PlantMachinery2025-01-012025-12-3106627288core:FurnitureFittings2025-01-012025-12-3106627288core:MotorVehicles2025-01-012025-12-310662728812025-01-012025-12-310662728812024-01-012024-12-3106627288core:UKTax2025-01-012025-12-3106627288core:UKTax2024-01-012024-12-3106627288core:PlantMachinery2024-12-3106627288core:FurnitureFittings2024-12-3106627288core:MotorVehicles2024-12-31066272882024-12-3106627288core:PlantMachinery2025-12-3106627288core:FurnitureFittings2025-12-3106627288core:MotorVehicles2025-12-3106627288core:PlantMachinery2024-12-3106627288core:FurnitureFittings2024-12-3106627288core:MotorVehicles2024-12-3106627288core:CurrentFinancialInstruments2025-12-3106627288core:CurrentFinancialInstruments2024-12-3106627288bus:OrdinaryShareClass12025-01-012025-12-3106627288bus:OrdinaryShareClass12025-12-3106627288bus:OrdinaryShareClass12024-12-3106627288core:BetweenTwoFiveYears2025-12-3106627288core:BetweenTwoFiveYears2024-12-3106627288core:MoreThanFiveYears2025-12-3106627288core:MoreThanFiveYears2024-12-3106627288bus:PrivateLimitedCompanyLtd2025-01-012025-12-3106627288bus:FRS1022025-01-012025-12-3106627288bus:Audited2025-01-012025-12-3106627288bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP